WASHINGTON — Vinay Prasad, a prime official on the Meals and Drug Administration who has been on the middle of recurring public controversies, is exiting the company for a second time.
Prasad will go away the FDA on the finish of April, and his alternative has not but been recognized, FDA Commissioner Marty Makary advised The Wall Avenue Journal.
STAT Plus: Beneath Vinay Prasad, workers at a key FDA middle concern talking out, search for the exits
An FDA spokesperson confirmed Prasad’s departure. Prasad didn’t instantly reply to requests for remark from STAT.
In a social media publish, Makary thanked Prasad for his work on the company, highlighting Prasad’s position in decreasing the variety of medical trials required to approve a drug, limiting Covid vaccine approvals to these over 65 or with threat elements, growing a brand new pathway for individualized medicines, and serving to launch a brand new speedy drug assessment program. Makary mentioned the identical in a word to employees, seen by STAT.
“He obtained an amazing quantity completed inside his one-year sabbatical from UCSF and can be returning again to his tutorial house later subsequent month,” Makary mentioned. “We are going to identify a successor earlier than his departure.”
His departure comes after a collection of controversial company choices on uncommon illness medicine by the Middle of Organic Analysis and Analysis, which Prasad oversees. It additionally comes a day after the Division of Well being and Human Companies, which oversees the FDA, held a press name during which a senior official bashed an experimental Huntington’s therapy — an unconventional step involving dialogue of a remedy being thought-about by regulators.
Prasad is just the most recent in a collection of dramatic departures by prime officers on the Trump administration’s FDA. The Middle for Drug Analysis and Analysis had 5 totally different administrators in 2025. Richard Pazdur, a longtime most cancers drug regulator, retired from the CDER director publish in December because of considerations that political officers have been corrupting the company’s scientific course of. George Tidmarsh, who held the position earlier than Pazdur, left amid allegations that he had used his regulatory perch to advance a vendetta in opposition to a former biotech colleague. Tidmarsh denies these allegations. Company leaders at decrease ranges have been pushed out, or voluntarily left for different alternatives at a gentle clip.
Prasad, an oncologist by coaching who was additionally serving because the FDA’s chief scientific and medical officer, oversaw the regulation of vaccines, gene therapies, and blood merchandise. Beforehand, he taught on the College of California San Francisco and was often known as a well being care provocateur, criticizing medical trial designs and the relationships between regulators, medical doctors, and business.
Beneath Prasad’s management, CBER has elevated scrutiny of uncommon illness medicine on the identical time Makary and others have been publicly stressing regulatory flexibility.
Prasad’s middle has not too long ago rejected no less than 5 cell and gene therapies that specialists consider doubtless might have acquired approval below earlier FDA officers.
In some circumstances, drugmakers have accused the company of reversing earlier agreements on medical trial designs. A drug to deal with a uncommon blood most cancers, for instance, was on the trail to FDA approval final 12 months earlier than the company rejected it final month, based mostly on considerations about medical knowledge that the corporate thought had been beforehand addressed.
The selections have spooked uncommon illness affected person advocates, who’ve questioned whether or not the company’s rhetoric on embracing flexibility for uncommon illness medicine matches up with its actions.
Prasad took over as CBER director in Might of 2025, however was fired in July after he angered uncommon illness group advocates and far-right influencer Laura Loomer, who’s near President Trump, along with his dealing with of a therapy for Duchenne muscular dystrophy. The administration modified course only a few weeks later, nevertheless, and employed him again after Makary vouched for him.
He didn’t return humbled, STAT beforehand reported. One in all his first strikes upon returning was to fireside the particular person in command of vaccine security and surveillance, putting in himself as an alternative. Prasad has pushed no less than seven leaders out of their positions. Eight company officers advised STAT in October that Prasad had created a piece setting that was rife with distrust and paranoia.
STAT Plus: Inside the autumn of Vinay Prasad on the FDA
Throughout his tenure, Prasad, as a key ally of Makary’s, performed a key position in a few of the company’s most essential initiatives. He led the committee charged with evaluating drug submissions bestowed with a “Commissioner’s Nationwide Precedence Voucher,” which ensures a regulatory choice inside one to 2 months. The position allowed him to weigh in on drug choices outdoors his purview as CBER director.
He additionally sought to carry vaccines to a regulatory stage that, in accordance with 12 former FDA commissioners, would possibly make it not possible for producers to develop new merchandise. Prasad and prime drug regulator Tracy Beth Høeg have wrested management of vaccine surveillance from profession employees. Most not too long ago, Prasad overruled employees by refusing to assessment a brand new flu vaccine from Moderna. The company in the end agreed to assessment the product after White Home strain.
The FDA and different well being companies have taken a extra vaccine-skeptical strategy below well being secretary Robert F. Kennedy Jr., a recognized vaccine critic.
Prasad, who lives in California, labored on the FDA’s Silver Spring, Md., campus only a few days per week. Nonetheless, employees members mentioned he sought an uncommon diploma of management over employees from afar, requiring them to make their calendars fully seen to him regardless of his personal calendar remaining personal. He advised employees to not notify their supervisors if he requested conferences with them.
4 officers advised STAT on the time that a number of workers had filed complaints about Prasad’s administration model with human sources.